Sorrento Therapeutics, Inc.
SRNE
|
$0.033
2M
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-98.88% volume)
Earnings Calendar: 2023-02-20
Market Cap: $ 18,192,278
http://www.sorrentotherapeutics.com
Sec Filling | Patents | 310 employees
(US) Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
cancer covid antibody t-cell ceiling
add to watch list Paper trade email alert is off
Press-releases
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
Published: 2024-03-27 (Crawled : 13:00) - globenewswire.com
SCLX | $1.145 -10.55% 680K
|
|
| O: -0.66%
H: 10.33%
C: 7.33%
company
Virpax Pharmaceuticals Reports 2023 Year-End Results
Published: 2024-03-26 (Crawled : 20:00) - biospace.com/
VRPX | $3.5303 1.2K
|
|
| O: -0.68%
H: 3.17%
C: 2.65%
virpax pharmaceuticals results
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
SCLX | $1.145 -10.55% 680K
|
|
| O: 0.72%
H: 2.89%
C: -2.14%
virpax wholly pharmaceuticals agreement
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024
Published: 2024-03-02 (Crawled : 00:20) - globenewswire.com
SRNE | $0.033 2M
|
Health Technology
| Email alert
Add to watchlist
SCLX | $1.145 -10.55% 680K
|
| Email alert
Add to watchlist
company
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Published: 2024-02-27 (Crawled : 13:30) - biospace.com/
VRPX | $3.5303 1.2K
|
|
| O: -14.39%
H: 7.35%
C: -0.24%
virpax pharmaceuticals
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement
Published: 2024-02-26 (Crawled : 22:00) - globenewswire.com
SCLX | $1.145 -10.55% 680K
|
|
| O: 1.45%
H: 15.24%
C: 10.0%
virpax wholly pharmaceuticals agreement
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $25.73 -0.7% 17M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
GILD | $67.44 -0.46% 2.3M
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.925 0.51% 470K
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
SCLX | $1.145 -10.55% 680K
|
|
| O: 3.82%
H: 5.76%
C: 1.04%
company
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
Published: 2023-11-17 (Crawled : 17:00) - biospace.com/
VRPX | $3.5303 1.2K
|
|
| O: 6.92%
H: 0.0%
C: -7.88%
nasdaq virpax pharmaceuticals
UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure
Published: 2023-10-27 (Crawled : 20:00) - globenewswire.com
SRNE | $0.033 2M
|
Health Technology
| Email alert
Add to watchlist
SCLX | $1.145 -10.55% 680K
|
| Email alert
Add to watchlist
company update order
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 55% | 45% |
Top 10 Gainers
WISA 4 | $5.33 204.57% 190M
|
Electronic Technology
TPET | $0.5189 124.54% 38M
|
n/a
SXTC | $1.78 52.14% 33M
|
Health Technology
JAGX | $0.1771 49.07% 540M
|
Health Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
FNCH | $2.98 32.74% 400K
|
Professional, Scientific, and T...
PALI | $5.51 32.45% 28M
|
Manufacturing
VERO | $0.804 31.8% 110K
|
Health Technology
Last 48 Hours Insiders Buying
RVP P 3587 | $1.06 -1.85% 48K
|
Health Technology
|
17:00
TPL P 12 | $591.105 1.23% 29K
|
Miscellaneous
|
16:01
HNRA | $2.81 19.07% 400K
|
n/a
|
15:02
TGEN | $0.67 16K
|
Utilities
|
14:30
RMCF | $3.6492 9.1K
|
Consumer Non-Durables
|
20:10